Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
Older Patients with Asthma Do Well with Reslizumab | RT
CINQAIR® (reslizumab) Injection – About Asthma Control
Reslizumab Overview - Creative Biolabs
Reslizumab | New Drug Approvals
NICE Recommends CINQAERO (reslizumab) for the Treatment of Severe Eosinophilic Asthma » FINCHANNEL
Dosing and Administration
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Teva files MAA for asthma treatment reslizumab
NICE changes mind and backs new drug for severe asthma | Nursing Times
Reslizumab | Teva UK
Medication Detail
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Israeli Pharma gets FDA Approval for Asthma Antibody
Teva filled Biologics License Application for reslizumab Archives • NCK Pharma
FDA approves Teva's Cinqair (reslizumab) Injection
Help eligible, commercially insured patients save on out-of-pocket costs for CINQAIR*
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Reslizumab
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
